Moreover, individuals with pathogenic RAD51C variants are not candidates for increased breast surveillance or prophylactic surgical interventions because there is no indication of an elevated risk of BC (Couch et al., 2017; Sopik et al., 2015), with the exception of triple negative breast cancer (Shimelis et al., 2018). This evidence concerns the gene RAD51C and breast cancer.